2. Search Result
Search Result
Results for "

TRAP activity

" in MedChemExpress (MCE) Product Catalog:

43

Inhibitors & Agonists

2

Fluorescent Dyes

2

Biochemical Assay Reagents

1

Peptides

7

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-A0004
    Decitabine
    Maximum Cited Publications
    168 Publications Verification

    5-Aza-2'-deoxycytidine; 5-AZA-CdR; NSC 127716

    		 DNA Methyltransferase Apoptosis Nucleoside Antimetabolite/Analog Cancer
    Decitabine (NSC 127716) is an orally active deoxycytidine analogue antimetabolite and a DNA methyltransferase inhibitor. Decitabine incorporates into DNA in place of cytosine can covalently trap DNA methyltransferase to DNA causing irreversible inhibition of the enzyme. Decitabine induces cell G2/M arrest and cell apoptosis. Decitabine has potent anticancer activity .
    Decitabine
  • HY-P0078
    TRAP-6
    5+ Cited Publications

    PAR-1 agonist peptide; Thrombin Receptor Activator Peptide 6

    		 Protease Activated Receptor (PAR) Inflammation/Immunology
    TRAP-6 (PAR-1 agonist peptide), a peptide fragment, is a selective protease activating receptor 1 (PAR1) agonist. TRAP-6 activates human platelets via the thrombin receptor. TRAP-6 shows no activity at PAR4 .
    TRAP-6
  • HY-123606
    GSK484
    45+ Cited Publications

    		 Protein Arginine Deiminase MHC Cardiovascular Disease Inflammation/Immunology
    GSK484 is a PAD4 inhibitor that effectively inhibits protein citrullination and the formation of neutrophil extracellular traps (NETs) by blocking the catalytic activity of PAD4. GSK484 suppresses the production of histone H3, MHC-I expression, CD8 + T cell activation, proliferation and inflammatory cytokine release. GSK484 reduces inflammation and bone destruction in collagen-induced rheumatoid arthritis, alleviates pain and mast cell activation in sickle cell disease, and improves myocardial ischemia-reperfusion injury and experimental colitis. In addition, GSK484 restores intestinal microbial homeostasis by reversing ferroptosis-induced dysbiosis. GSK484 can be used to study the disease mechanisms of rheumatoid arthritis, sickle cell disease, thrombosis, myocardial injury, colitis and other conditions .
    GSK484
  • HY-135152
    CYPMPO

    		Reactive Oxygen Species (ROS) Cancer
    CYPMPO is a spin-trapping reagent. CYPMPO, a cyclic DEPMPO-type nitrone, is evaluated for spin-trapping capabilities toward hydroxyl and superoxide radicals. anti-oxidant and anti-tumor?activity .
    CYPMPO
  • HY-125176
    G907
    1 Publications Verification

    		 Bacterial Infection
    G907 is a selective antagonist of ATP-binding cassette (ABC) transporter MsbA with anti-microbial activity. G907 inhibits E. coli MsbA with an IC50 value of 18 nM. G907 traps MsbA in an inward-facing, lipopolysaccharide-bound conformation by wedging into an architecturally conserved transmembrane pocket .
    G907
  • HY-141466
    Crotonyl-CoA

    		Endogenous Metabolite Histone Acetyltransferase Infection Metabolic Disease Inflammation/Immunology
    Crotonyl-CoA, a high-energy acyl donor, is an intermediate in the fermentation of butyric acid, and in the metabolism of lysine and tryptophan. Crotonyl-CoA is important in the metabolism of fatty acids and amino acids. Crotonyl-CoA acts as a substrate for p300’s histone crotonyltransferase activity, competing with acetyl-CoA for p300-mediated histone acylation reactions. Crotonyl-CoA regulates global and gene-specific histone crotonylation levels in cells, with cellular concentration changes altering histone crotonylation at regulatory elements of activated genes. Crotonyl-CoA serves as the substrate for crotonyl-CoA reductase/carboxylase (CCRC)-catalyzed NADPH-mediated reduction and carbon dioxide trapping to form unusual alkylmalonyl-CoA polyketide synthase extender units. Crotonyl-CoA can be used for the research of LPS-induced inflammatory response .
    Crotonyl-CoA
  • HY-141466A
    Crotonyl-CoA tetrasodium

    		Endogenous Metabolite Histone Acetyltransferase Infection Metabolic Disease Inflammation/Immunology
    Crotonyl-CoA tetrasodium, a high-energy acyl donor, is an intermediate in the fermentation of butyric acid, and in the metabolism of lysine and tryptophan. Crotonyl-CoA tetrasodium is important in the metabolism of fatty acids and amino acids. Crotonyl-CoA tetrasodium acts as a substrate for p300’s histone crotonyltransferase activity, competing with acetyl-CoA for p300-mediated histone acylation reactions. Crotonyl-CoA tetrasodium regulates global and gene-specific histone crotonylation levels in cells, with cellular concentration changes altering histone crotonylation at regulatory elements of activated genes. Crotonyl-CoA tetrasodium serves as the substrate for crotonyl-CoA reductase/carboxylase (CCRC)-catalyzed NADPH-mediated reduction and carbon dioxide trapping to form unusual alkylmalonyl-CoA polyketide synthase extender units. Crotonyl-CoA tetrasodium can be used for the research of LPS-induced inflammatory response .
    Crotonyl-CoA tetrasodium
  • HY-15595A
    360A iodide
    3 Publications Verification

    360 A iodide

    		 G-quadruplex Telomerase Cancer
    360A iodide is a selective stabilizer of G-quadruplex, and also inhibits telomerase activity with an IC50 of 300 nM for telomerase in TRAP-G4 assay.
    360A iodide
  • HY-115691
    STY-BODIPY

    Styrene-BODIPY; Styrene-Conjugated BODIPY

    		 Fluorescent Dye Others
    STY-BODIPY (Styrene-BODIPY; Styrene-Conjugated BODIPY) is a styrene-conjugated fluorescent probe used to measure the activity of radical-trapping antioxidants (RTAs)> .
    STY-BODIPY
  • HY-130644
    iRucaparib-AP6
    2 Publications Verification

    		 PROTACs PARP Cancer
    iRucaparib-AP6 is a highly efficient and specific PROTAC PARP1 degrader. iRucaparib-AP6, a non-trapping PARP1 degrader, blocks both the catalytic activity and scaffolding effects of PARP1 .
    iRucaparib-AP6
  • HY-107194
    NSC12

    		FGFR c-Myc DNA/RNA Synthesis Caspase Reactive Oxygen Species (ROS) Cancer
    NSC12 is an orally active pan-FGF trap. NSC12 inhibits the interaction between FGF2/FGFR. NSC12 suppresses the phosphorylation of FGFR3. NSC12 reduces c-Myc levels, induces DNA damage, triggers the cleavage of Caspase 3, and promotes ROS production. NSC12 exhibits anticancer activity against lung cancer and multiple myeloma .
    NSC12
  • HY-D1491A
    Fast Red Violet LB Zinc chloride

    		Fluorescent Dye Others
    Fast Red Violet LB Zinc chloride is a stain that stains tartrate-resistant acid phosphatase (TRAP) and Fast Red Violet LB Zinc chloride can be used to stain alkaline phosphatase (ALP) activity .
    Fast Red Violet LB Zinc chloride
  • HY-A0004R
    Decitabine (Standard)

    5-Aza-2'-deoxycytidine (Standard); 5-AZA-CdR (Standard); NSC 127716 (Standard)

    		 Reference Standards DNA Methyltransferase Apoptosis Nucleoside Antimetabolite/Analog Cancer
    Decitabine (Standard) is the analytical standard of Decitabine. This product is intended for research and analytical applications. Decitabine (NSC 127716) is an orally active deoxycytidine analogue antimetabolite and a DNA methyltransferase inhibitor. Decitabine incorporates into DNA in place of cytosine can covalently trap DNA methyltransferase to DNA causing irreversible inhibition of the enzyme. Decitabine induces cell G2/M arrest and cell apoptosis. Decitabine has potent anticancer activity .
    Decitabine (Standard)
  • HY-170620
    PARP1 PROTAC 180055
    1 Publications Verification

    		 PROTACs PARP Cancer
    PARP1 PROTAC 180055 (Compound 180055) is a selective PARP1 PROTAC degrader (DC50 in T47D and MDA-MB-231 cell lines is 180 nM and 240 nM, respectively). PARP1 PROTAC 180055 promotes ubiquitination and degradation of PARP1 as well as inhibits PARP1 enzyme activity without a noticeable DNA trapping effect. PARP1 PROTAC 180055 inhibits tumors carrying BRCA mutations with a minor impact on the growth of normal cells (Pink: PARP1 ligand (HY-10617A); Blue: E3 ligase VHL ligand (HY-125845); Black: linker (HY-W014787)) .
    PARP1 PROTAC 180055
  • HY-138869
    AubipyOMe

    		Endogenous Metabolite Cancer
    AubipyOMe serves as a potent inhibitor of tartrate-resistant acid phosphatase (TRAP/ACP5), a metalloenzyme found in activated osteoclasts and macrophages, demonstrating IC50 values of 1.3 μM for TRAP5a and 1.8 μM for TRAP5b, while effectively inhibiting TRAP activity in extracts from murine macrophages and human lung tissue.
    AubipyOMe
  • HY-115781
    DN401
    1 Publications Verification

    Panvotinib-401; Pan-401

    		 HSP Cancer
    DN401 is a potent TRAP1 inhibitor with an IC50 of 79 nM. DN401 shows a weak inhibition of Hsp90 (IC50 of 698 nM). DN401 inactivates mitochondrial TRAP1 and has potent anticancer activities .
    DN401
  • HY-15595
    360A

    		G-quadruplex Telomerase Cancer
    360A is a selective stabilizer of G-quadruplex, and also inhibits telomerase activity with an IC50 of 300 nM for telomerase in TRAP-G4 assay.
    360A
  • HY-132995
    DP-1

    		Drug Metabolite Others
    DP-1, a degradation product of SDC-TRAP-0063, is a fragment of Ganetespib. Ganetespib is a heat shock protein 90 (HSP90) inhibitor with anti-tumor activity .
    DP-1
  • HY-W002438
    6-Hydroxyindole

    		Biochemical Assay Reagents Endogenous Metabolite OAT Ferroptosis Neurological Disease Metabolic Disease
    6-Hydroxyindole is an orally active, endogenous long-acting OATP1B1 inhibitor. 6-Hydroxyindole does not alter the cell surface expression or subcellular localization of OATP1B1. 6-Hydroxyindole protects cells against Ferroptosis. 6-Hydroxyindole possesses intrinsic radical-trapping antioxidant activity. 6-Hydroxyindole serves as a component of oxidative hair dyes. 6-Hydroxyindole can be used in research related to renal failure and neurodegenerative diseases .
    6-Hydroxyindole
  • HY-W996116
    AZM198

    		Glutathione Peroxidase Cardiovascular Disease Neurological Disease Inflammation/Immunology
    AZM198 is an orally active myeloperoxidase (MPO) inhibitor. AZM198 irreversibly inactivates MPO (IC50=0.015 μM) via covalent binding to the heme prosthetic group, preferentially targets extracellular MPO activity, and reduces neutrophil extracellular trap formation, reactive oxygen species production and degranulation. AZM198 increases the fibrous cap thickness of atherosclerotic plaques, reduces lesion area, ameliorates hepatic steatosis and fibrosis in non-alcoholic steatohepatitis, and alleviates proteinuria and inflammatory infiltration associated with glomerulonephritis. AZM198 also decreases circulating levels of high-sensitivity Cardiac Troponin I and IL-1β, and mitigates endothelial cell injury. Therefore, AZM198 is suitable for research on various MPO-related diseases, including atherosclerotic cardiovascular disease, myocardial infarction, ischemic stroke, non-alcoholic steatohepatitis and crescentic glomerulonephritis .
    AZM198
  • HY-N7646
    Curculigoside B

    		Others Others
    Curculigoside B, a phenolic glycoside isolated from Curculigo orchioides, enhances the osteoblast proliferation, decreases the area of bone resorption pit, osteoclastic formation and TRAP activity. Antiosteoporotic and antioxidative activities .
    Curculigoside B
  • HY-W008820R
    Glutaric acid (Standard)

    		Reference Standards Endogenous Metabolite Metabolic Disease
    Glutaric acid (Standard) is the analytical standard of Glutaric acid. This product is intended for research and analytical applications. Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I . In Vitro: Glutaric acid (GA) at concentrations of 1 and 2 mM is able to reduce TRAP measurement by up to 28% in a dose-dependent manner (β=0.77; P<0.001). Furthermore, a significantly inverse correlation is also verified between chemiluminescence and TRAP (β=0.81; P<0.001). Glutaric acid does not alter the activities of Cat and SOD, but strongly inhibits (up to 46%) the activity of GPx even at the lower concentration used (0.5 mM). It is observed that the metabolite inhibits this activity in a dose-dependent manner at concentrations as low as 0.05 mM .
    Glutaric acid (Standard)
  • HY-147696
    SMTIN-T140

    		HSP AMPK Reactive Oxygen Species (ROS) Cancer
    SMTIN-T140 (compound 6a) is a potent TRAP1 (tumor-necrosis-factor-receptor associated protein 1) inhibitor, with an IC50 of 1.646 μM. SMTIN-T140 shows anticancer activity. SMTIN-T140 leads to mitochondrial dysfunction, increases mitochondrial ROS production and activates AMPK. SMTIN-T140 potently suppressed tumor growth without any noticeable in vivo toxicity in a mouse model xenografted with PC3 prostate cancer cells .
    SMTIN-T140
  • HY-D1491
    Fast Red Violet LB

    		Fluorescent Dye Others
    Fast Red Violet LB is a dye for staining tartrate resistant acid phosphatase (TRAP). Fast Red Violet LB can be used for alkaline phosphatase (ALP) activity staining .
    Fast Red Violet LB
  • HY-166309
    Crotonyl-CoA tetralithium

    		Endogenous Metabolite Histone Acetyltransferase Infection Metabolic Disease Inflammation/Immunology
    Crotonyl-CoA tetralithium, a high-energy acyl donor, is an intermediate in the fermentation of butyric acid, and in the metabolism of lysine and tryptophan. Crotonyl-CoA tetralithium is important in the metabolism of fatty acids and amino acids. Crotonyl-CoA tetralithium acts as a substrate for p300’s histone crotonyltransferase activity, competing with acetyl-CoA for p300-mediated histone acylation reactions. Crotonyl-CoA tetralithium regulates global and gene-specific histone crotonylation levels in cells, with cellular concentration changes altering histone crotonylation at regulatory elements of activated genes. Crotonyl-CoA tetralithium serves as the substrate for crotonyl-CoA reductase/carboxylase (CCRC)-catalyzed NADPH-mediated reduction and carbon dioxide trapping to form unusual alkylmalonyl-CoA polyketide synthase extender units. Crotonyl-CoA tetralithium can be used for the research of LPS-induced inflammatory response .
    Crotonyl-CoA tetralithium
  • HY-N7314
    Asebogenin

    		Syk Inflammation/Immunology
    Asebogenin has antimalarial activity in vitro . Asebogenin can inhibit the phosphorylation of Syk, thereby effectively suppressing platelet activation and the formation of neutrophil extracellular traps .
    Asebogenin
  • HY-121282B
    Mepazine acetate

    Pecazine acetate

    		 Apoptosis MALT1 Others
    Mepazine acetate (Pecazine acetate) is a drug that has the activity to inhibit the protease activity of MALT1. Mepazine acetate is often used to study the role of MALT1 in biology. Treatment of mouse bone marrow precursor cells with mepazine acetate strongly inhibited RANK ligand (RANKL)-induced osteoclast formation. Mepazine acetate also inhibited the expression of multiple osteoclast markers such as TRAP, feline hepsin K, and calcitonin. The protective effect of mepazine acetate was not affected by MALT1 deficiency. The mechanism of action of mepazine acetate may involve MALT1-independent mechanisms, and this aspect needs to be considered in future studies .
    Mepazine acetate
  • HY-N8789
    2-Hydroxymethyl-3-hydroxyanthraquinone

    		Phosphatase Others
    2-Hydroxymethyl-3-hydroxyanthraquinone is an antiosteoporotic compound that inhibits osteoclastic tartrate-resistant acid phosphatase (TRAP) activity .
    2-Hydroxymethyl-3-hydroxyanthraquinone
  • HY-132995A
    DP-1 hydrochloride

    		Drug Metabolite Cancer
    DP-1 hydrochloride, a degradation product of SDC-TRAP-0063, is a fragment of Ganetespib. Ganetespib is a heat shock protein 90 (HSP90) inhibitor with anti-tumor activity .
    DP-1 hydrochloride
  • HY-144830
    6BrCaQ

    		HSP Cancer
    6BrCaQ is a potent mitochondrial heat shock protein TRAP1 inhibitor, with antiproliferative activity. 6BrCaQ can be used in the synthesis of 6BrCaQ-TPP conjugates .
    6BrCaQ
  • HY-138241
    PBD-BODIPY

    		Fluorescent Dye Others
    PBD-BODIPY is a probe for the spectrophotometric measurement of autoxidation reactions. Co-autoxidation of the PBD-BODIPY signal carrier and a hydrocarbon co-substrate can be quantified by monitoring loss of absorbance at 591 nm. PBD-BODIPY has been used to measure the activity of radical-trapping antioxidants in cell-free assays. It has also been used as a fluorescent probe for the detection of epoxidation activity.
    PBD-BODIPY
  • HY-168002
    MPO-IN-8

    		Glutathione Peroxidase Inflammation/Immunology
    MPO-IN-8 is an orally active myeloperoxidase (MPO) inhibitor. MPO-IN-8 can inhibit the generation of hypochlorous acid in neutrophils and the release of extracellular traps (NETosis). In mice with gouty arthritis, MPO-IN-8 can reduce swelling, lower peroxidase activity, and decrease IL-1β levels .
    MPO-IN-8
  • HY-151999
    KRAS G12C inhibitor 65

    		Ras Cancer
    KRAS G12C inhibitor 65 is a potent and covalent KRAS G12C inhibitor that traps KRAS G12C in the GDP-bound state. KRASG12C IN-1 exhibits potent antitumor activity against KRAS-mutant non-small cell lung cancer .
    KRAS G12C inhibitor 65
  • HY-144831
    6BrCaQ-C10-TPP

    		HSP Cancer
    6BrCaQ-C10-TPP is a potent mitochondrial heat shock protein TRAP1 inhibitor, with antiproliferative activity in various human cancer cells (IC50=0.008-0.30 μM). 6BrCaQ-C10-TPP can also induces mitochondrial membrane disturbance .
    6BrCaQ-C10-TPP
  • HY-157157
    PAD4-IN-3

    		Protein Arginine Deiminase Cancer
    PAD4-IN-3 (compound 4B) is a PAD4 inhibitor with antitumor activity in vitro and in vivo. PAD4-IN-3 was covalently linked to RGD sequence peptide-modified chitosan (K-CRGDV), resulting in an enhanced oxidative stress-responsive nanoagent. K-CRGDV-PAD4-IN-3 can actively target tumors, inhibit PAD4 activity, block the formation of neutrophil extracellular traps (NETs), and improve the tumor immune microenvironment in response to the tumor microenvironment .
    PAD4-IN-3
  • HY-A0004S
    Decitabine-13C5

    5-Aza-2'-deoxycytidine-13C5; 5-AZA-CdR-13C5; NSC 127716-13C5

    		 Isotope-Labeled Compounds DNA Methyltransferase Nucleoside Antimetabolite/Analog Apoptosis Cancer
    Decitabine- 13C5 (5-Aza-2'-deoxycytidine- 13C5) is 13C labeled Decitabine. Decitabine (NSC 127716) is an orally active deoxycytidine analogue antimetabolite and a DNA methyltransferase inhibitor. Decitabine incorporates into DNA in place of cytosine can covalently trap DNA methyltransferase to DNA causing irreversible inhibition of the enzyme. Decitabine induces cell G2/M arrest and cell apoptosis. Decitabine has potent anticancer activity .
    Decitabine-13C5
  • HY-170959
    NYY-6a

    		Ferroptosis Neurological Disease Metabolic Disease
    NYY-6a is a Ferroptosis inhibitor. NYY-6a shows significant inhibitory activity against RSL3-induced ferroptosis across 786-O and HT-1080 cells with EC50s of 52 and 50 nM, respectively. NYY-6a functions as a radical trapping antioxidant (RTA) with efficacy of diminishing lipid peroxidation comparable to ferrostatin-1 and liproxtatin-1. NYY-6a is potential for ferroptosis related pathologies reasearch .
    NYY-6a
  • HY-114159
    GGTI-2166

    		GGTase Metabolic Disease
    GGTI-2166 is a geranylgeranyltransferase I (GGTase I) inhibitor. GGTI-2166 blocks geranylgeranylation modification of target proteins. GGTI-2166 inhibits RANKL- or TNF-α-induced pre-osteoclast formation and TRAP activity. GGTI-2166 is applicable to research on osteoclast differentiation .
    GGTI-2166
  • HY-181014
    Glucocorticoid receptor modulator 5

    		Glucocorticoid Receptor NF-κB AP-1 Inflammation/Immunology
    Glucocorticoid receptor modulator 5 (Compound D8) is a selective, orally active Glucocorticoid receptor modulator. Glucocorticoid receptor modulator 5 shows extremely high transrepression activity (TRNF-κB IC50 = 0.0009 μM, TRAP-1 IC50 = 0.0005 μM). Glucocorticoid receptor modulator 5 exerts its anti-inflammatory activity by interacting directly with the Glucocorticoid receptor signaling pathway. Glucocorticoid receptor modulator 5 significantly alleviates dermatitis and autoimmune hepatitis .
    Glucocorticoid receptor modulator 5
  • HY-N11884
    Ubiquinone Q3

    		Endogenous Metabolite Inflammation/Immunology
    Ubiquinone Q3 is an isoprenoid-chain ubiquinone homologue found in Saccharomyces cerevisiae, Escherichia coli, and Rhodospirillum rubrum. Ubiquinone Q3 has antioxidant activity and traps lipid peroxyl radicals .
    Ubiquinone Q3
  • HY-182302
    SMTIN-P01

    		Drug Derivative HSP Cancer
    SMTIN-P01 is a TRAP1 inhibitor that is selective for cytosolic Hsp90 and accumulates in mitochondria. SMTIN-P01 binds to the ATP-binding site of TRAP1 as an ATP mimic, thereby inhibiting ATPase and foldase activities. SMTIN-P01 induces mitochondrial membrane depolarization and proteolytic degradation in cancer cells. SMTIN-P01 exhibits significant cytotoxicity, but shows extremely low toxicity to primary mouse hepatocytes, and does not interfere with SIRT3-related functions or the levels of cytosolic Hsp90 substrates. SMTIN-P01 has important application value in cancer-related research .
    SMTIN-P01
  • HY-NP216
    PA-IIL

    LecB

    		 Integrin Endogenous Metabolite Bacterial Infection
    PA-IIL (LecB) is a lectin produced by Pseudomonas aeruginosa. PA-IIL binds to glycosylated β1-integrin, fucose-containing glycosphingolipids, fucosylated/mannosylated neutrophil glycoconjugates, and pre-formed neutrophil extracellular traps. PA-IIL disrupts host defenses: it creates favorable conditions for Pseudomonas aeruginosa infection and dissemination by modulating the bactericidal activity of neutrophils, impairing the trafficking and recruitment of immune cells, and compromising the repair capacity of epithelial barriers. PA-IIL can be used in studies related to Pseudomonas aeruginosa infection .
    PA-IIL
  • HY-182757
    Y1693

    		RANKL/RANK Nuclear Factor of activated T Cells (NFAT) Cathepsin Metabolic Disease Inflammation/Immunology
    Y1693 is an orally active RANKL inhibitor with a Kd of 5.03 μM for hRANKL. Y1693 inhibits the activation of the downstream c-fos/NFATc1 signaling pathway by blocking its interaction with RANK. Y1693 significantly inhibits RANKL-induced osteoclast differentiation, F-actin ring formation and bone resorptive activity, while downregulating the mRNA and protein expressions of TRAP, cathepsin K, c-fos and NFATc1. Y1693 shows no obvious cytotoxicity to bone marrow-derived macrophages and osteoclast precursor cells, and exhibits favorable ADME properties. Y1693 improves ovariectomy-induced osteoporosis in mice and reverses ligation-induced periodontal alveolar bone loss. Y1693 is applicable to research related to osteoporosis and periodontal diseases .
    Y1693

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: